Podcasts about Agrawal

Key Learnings/Takeaways: Attendees gained insights from Dr. Agrawal's personal journey, including:The power of "crucible experiences" in shaping leadership skills.Strategies for building a successful coaching practice.The necessity of continuous learning and adapting to change.Essential qualities for effective leadership in today's dynamic environment.The ethical and practical applications of AI within the coaching profession. The discussion also highlighted the significance of self-awareness, trust-building, and embracing vulnerability in both leadership and coaching contexts. If you're passionate about coaching and want to take your skills to the next level, explore Coacharya's range of ICF-accredited training programs. Visit our website for more information! https://coacharya.com/events/ #LeadershipDevelopment #ExecutiveCoaching #CareerAdvice #PersonalDevelopment #HRLeadership #ArtificialIntelligence #CoachEducation #ICFAccreditation #Coacharya #Mastermind #MentorshipThis episode was recorded on 02 April, 2025 as part of the Mastermind Mentor Webinar SeriesYou can watch the recording on our YouTube channel.  If you like this episode, please subscribe to our podcast and connect with us on the links below.  Thank you for your support!Contact Us https://coacharya.com/contactWebsite https://coacharya.comWebinars https://coacharya.com/events/LinkedIn https://www.linkedin.com/company/coacharyaFacebook https://www.facebook.com/CoacharyaTwitter https://twitter.com/coacharyaInstagram https://www.instagram.com/coacharya

Dr. Vamsi Velcheti and Dr. Charu Aggarwal discuss the evolution of ctDNA as a critical tool in precision oncology and its implications for lung cancer management, including its potential role in the early-stage setting. TRANSCRIPT Dr. Vamsi Velcheti: Hello. I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I am a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health.  The management of small cell lung cancer has rapidly evolved over the past few decades, and today, molecular testing and biomarker testing for lung cancer are absolutely critical in terms of designing treatment options for our patients with metastatic non-small cell lung cancer. Today, I'm delighted to be joined by Dr. Charu Aggarwal for a discussion on ctDNA (circulating tumor DNA) and the role of ctDNA in lung cancer management. Dr. Aggarwal is the Leslye Heisler Professor of Lung Cancer Excellence and section chief of thoracic and head and neck oncology at University of Pennsylvania Abramson Cancer Center.  You'll find our full disclosures in the transcript of that episode.  Dr. Agrawal, it's great to have you on the podcast today. Thank you for being here. Dr. Charu Aggarwal: Thank you for having me. Dr. Vamsi Velcheti: Let's start off with setting the stage for ctDNA technology. These technologies have rapidly evolved from experimental conceptual stage to essential clinical tools for day-to-day clinical practice. Could you briefly discuss how recent advancements in ctDNA technologies are shaping our approach to precision medicine, especially in lung cancer? Dr. Charu Aggarwal: Absolutely. And you know, I think we need to just level set a little bit. What exactly is circulating tumor DNA? This is a way to assess exactly that. Every tumor sheds little pieces of tumor-derived DNA into the bloodstream, and this occurs in a variety of solid tumors. But now we have the technology to be able to derive this DNA that's actually being shed from the tumor into the bloodstream, these minute fragments of DNA, take them out, amplify them and sequence them with a variety of different mechanisms. They can be DNA sequencing alone, they can be DNA and RNA sequencing, they can be whole transcriptome sequencing. The technology, as you rightly pointed out, Dr. Velcheti, has significantly improved from just being able to look at circulating tumor DNA to now being able to amplify it, sequence it, and use it to offer personalized therapy. I think lung cancer is definitely the poster child for such an approach as we have a lot of data that has shown clinical utility and validity of being able to use circulating tumor DNA next-generation gene sequencing to guide therapy. Dr. Vamsi Velcheti: There have been so many technological leaps. It's really impressive how far we've come to advance these sequencing platforms. Recent advances with AI and machine learning are also playing important roles in interpreting ctDNA data. How are these computational advances really enhancing clinical decision-making in day-to-day clinical practice? Dr. Charu Aggarwal: I think while we have firmly established the role of ctDNA in the management of patients with metastatic lung cancer, some of the approaches that you talked about are still experimental. So let me backtrack a little bit and set the stage for how we use ctDNA in clinical practice right now. I think most patients, when they come in with a new diagnosis of stage IV lung cancer, we want to test for biomarkers. And this should actually be the established standard. Now included in the NCCN guidelines and actually also international guidelines, is to consider using blood-based testing or plasma-based testing to look for biomarkers, not just tissue-based testing which had been our historical standard, but to use these plasma guided approaches to identify the seven to nine biomarkers that may be truly implicated in either first- or second-line therapy that are called as your immediately actionable mutations.  What you're talking about is AI computational methods. I think there's a lot of excitement about how we can use genomic signatures that are derived from either tissue or ctDNA-based biomarker testing, combine it with radiomic features, combine it with histologic features, look at H & E patterns, use AI algorithmic learning to be able to actually predict recurrence scores, or can we actually come up with predictive signatures that may be extremely helpful?  So, I think some of the techniques and technologies that you're talking about are incoming. They are provocative. I think they're very exciting, but very early. Dr. Vamsi Velcheti: I think it's really amazing how many advances we have with these platforms. You know, the challenge really is the significant gap in terms of uptake of molecular testing. Even today, in 2025, there are significant gaps in terms of all metastatic lung cancer patients being tested for all biomarkers.  So, why do you think there's such a challenge in testing patients with lung cancer? In most academic practices, we try to achieve 100% testing for all our patients, but we know from recent studies that that's not the case across the country. What do you think the gaps are? Dr. Charu Aggarwal: Biomarker testing is so essential, like you pointed out, for us to be able to guide the right therapy for our patients. And we see this in our practice every day as you and I see patients with lung cancer, that a large proportion of our patients either don't get tested or they start therapy before their test results come back. So, I think this is a real problem.  However, to add some optimism to this problem, I do think that we are making a move in the right direction. So, four or five years ago, there was a lot of data being presented at national meetings, including ones from the American Society of Clinical Oncology, where we saw that, nationally, the rates of biomarker testing were probably in the rate of 40 to 50%. However, now with the availability of both tissue and plasma, I do think that the rates of biomarker testing are increasing. And if you were to survey a sample or even perform retrospective data research, I believe that the number is closer to 70% of all patients with metastatic non-small cell lung cancer.  And you know, you asked why is it not 100%? I think there are many reasons. I think the number one reason is tissue availability. Many times, the biopsies are small, or the tumor is very necrotic. So, either the tissue quantity itself is small, or the tissue quantity is insufficient to perform gene sequencing. And that's exactly where plasma comes in. When you don't have tissue availability, we have shown, as have others, that you can use plasma effectively to increase the proportion of patients who are not only tested but also receive the right therapy. I think there are also other barriers, including inertia. You know, I think this is both patient and physician inertia, where patients want to get started quickly, they don't want to wait. Physicians are very busy and sometimes want to be able to deliver treatment as soon as possible. We have seen there are some institutional barriers. Not every institution has in-house gene sequencing testing. So how do you really operationalize, send out these tests in a fast, efficient manner so that you get results back? Is it a pathologist who sends out the test? Is it the medical oncologist? Is it the pulmonologist or the interventionalist? I think there is this need to develop reflex testing mechanisms which some institutions do really well and some don't. And then finally, there are financial implications as well. How do we do this in a most cost-efficient fashion?  So there are many barriers, but I'm happy to say that we are making a move in the right direction as we are understanding that it's important to do it, it's easy to do it maybe with a value add of plasma, and finally, as you said, you know, as these technologies become more available, they're actually getting more cost-effective. Dr. Vamsi Velcheti: Dr. Aggarwal, you've been at the cutting edge of these advanced platforms and testing. So, what do you do in UPenn? How do you handle all these barriers and what is your workflow for patients in University of Pennsylvania? Dr. Charu Aggarwal: One of the things that I mentioned to you was there may be institutional barriers when it comes to gene sequencing. So, we actually, several years ago now, instituted a very robust reflex testing paradigm where almost all of our patients, regardless of stage, with a non-squamous non-small cell lung cancer diagnosis, would automatically be reflexively sent to our molecular pathology lab where they would get gene sequencing both for the DNA as well as with an RNA fusion-based platform. And the reason we did this was because we wanted to expedite and reduce the turnaround time. We also wanted to ensure that we were not just doing DNA testing, which I think is really important for our listeners here. There are many fusions as well as certain skipping mutations like MET exon 14 that may be missed on DNA testing alone. So, it's really incredibly important to run both DNA and RNA samples.  So, we do this routinely, and based on our research and others, what we also do routinely is that we send concurrent tissue and liquid biopsies or plasma MGS testing upon initial diagnosis. For example, if a patient comes in with a diagnosis of stage IV non-small cell lung cancer, their tissue might already be at my molecular pathology lab based on the reflex mechanism that I just described to you. But upon their initial meeting with me, we will send off plasma. And I will tell you this, that Penn is not just one institution, right? We have a large network of sites. And as part of my research, one of the things that we wanted to do was implement wide scale means to improve biomarker testing. And we have done this with the use of technology like you mentioned, Dr. Velcheti: How can we actually use AI? How can we leverage our electronic medical record to identify these patients? So, we have a nudge-based mechanism which actually facilitates the pending of orders for biomarker testing for patients with new diagnosis of metastatic non-small cell lung cancer. And we are looking at our rates of biomarker testing but also rates of completion of biomarker testing before first-line therapy started. So many of our participating sites are clusters for our randomized control trial to increase molecular testing. And I'm really excited about the fact that we're able to implement it not just at our main satellite, downtown Penn Hospital, but also across our community. Dr. Vamsi Velcheti: I think that's great. Thank you so much for those insights, Dr. Aggarwal. I think it's so important because having the best technology is just not enough. I think implementation science is actually a real thing. And I think we need to all learn from each other, advance these things.  So, I want to ask you about the new emerging paradigm in terms of using ctDNA. Of course, in the metastatic setting, we've been using ctDNA for molecular profiling for a while now. But the recent data around monitoring early-stage disease, especially post-operative monitoring, is an exciting area. There are a lot of opportunities there. Could you please talk us through the emerging data in lung cancer and how do we incorporate ctDNA-based monitoring MRD or should we even do that right now? Is the data ripe enough for us to kind of deploy this in a clinical setting? Dr. Charu Aggarwal: I think using ctDNA in the early-stage setting is our next frontier in lung cancer. I think naturally we have been able to successfully deploy this in the stage 4 setting. It made a meaningful difference in the lives of our patients, and we are a little bit behind the A ball in terms of how MRD is used in lung cancer. Because, you know, colorectal cancer has already done large-randomized trials based on ctDNA and MRD. It's routinely used in hematological malignancy. So, it makes sense that we should start to use it.  However, when I say this, I say this with excitement, but also a little bit of gentle caution saying that we actually don't quite have the prospective randomized data just yet on how to deploy. Yes, intuitively we would say that if you detect ctDNA and MRD, that patient is at higher risk. So, we identify that, but we actually don't know what to do with the second part of that information once you identify a patient with high risk. Are there other techniques that we can then come in with or other drugs that we can come in with to modify that risk? And that's the thing that I think we don't have right now. The other thing that we don't have right now is the timing of the assay, when to use it. Is it to be tested in the pre-op setting? Is the post-op test the best timing, or is it monitoring and dynamics of ctDNA that are most important? And the third thing I will say in terms of precautionary cause is that we don't know which test just yet. There are actually a few commercially available tests out in the market right now. We know about them and I'm sure our community colleagues know about them. Some of them even have Medicare approval. However, many of these tests are currently tissue informed. We don't have tissue uninformed tests. And what does that mean? Tissue uninformed means that you actually take a piece of tumor tissue, you sequence that tumor and based on the gene profile of that tumor, you actually design a panel that can then be used to track the mutations in the blood-based pack. This requires, as the name implies, a tumor. So can this be used in the pre-op setting is a large question. Because coming back to the idea of tissue availability, you and I both know that when we get FNAS and we use it for PDL-1 testing and we use it for gene sequencing, there often isn't enough tissue left for us to then either do whole genome sequencing or even whole transcriptome sequencing, which may be required to build some of these assays.  I think the future lies in this idea of tumor uninformed assays because if we could go to a blood only or a plasma only approach using novel signatures like proteomics or methylation, I think that's where the future is. But we're still a little bit early in the discovery stages of those, as well as to come are the validation stages so that we can be confident that these blood-only assays may actually give us an answer.  So, with those three cautionary notes, I would say that optimism is still very high. I think ctDNA MRD is the right place to think about. We need to do this for our patients to better identify high-risk patients and to think about means to escalate treatment for them. Dr. Vamsi Velcheti: Yeah, I completely agree, and I think with all the changes and evolution of treatments in the management of early-stage lung cancer now with neoadjuvant and adjuvant, there's really a need for an escalation and de-escalation of therapies post-operatively. And I think it's a huge opportunity. I think we all could learn from our colorectal colleagues. I think they've done a really good job at actually doing prospective trials in this setting. I think we're kind of a little behind here.  Dr. Charu Aggarwal: I think in the metastatic setting there are ongoing trials to look at this exact question. How do you choose an appropriate first-line therapy, a monitor ctDNA at the six-week trial? It's being evaluated in a trial called the “Shedders” trial, where if patients are still ctDNA positive at six weeks, then you can escalate treatment because they haven't “cleared” their ctDNA. There has been a lot of research that has shown that lack of ctDNA clearance in the metastatic setting may be a poor prognostic factor. We and others have shown that if you do clear your ctDNA or if you have a reduction in ctDNA load overall, that that is directly related to both an improved progression-free survival and overall survival. This has been shown with both tissue informed and uninformed assays. So I think it's very clear that yes, you can track it. I think the question is: Can you apply that data to the early-stage setting? And that's an open research question. A lot of groups are looking at that and I think it's completely reasonable, especially to determine duration of therapy, to determine optimal timing, optimal timing of scans even. And I think these are just such interesting questions that will be answered in the future. Dr. Vamsi Velcheti: And also like a kind of early detection of resistance patterns that might inform early initiation of combination strategies. And I think it's a lot of opportunities I think yet to be explored. A lot of exciting things to come and I'm sure we'll kind of see more and more data in the next few years.  Dr. Aggarwal, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been a pleasure to have you on the podcast today. Hope to see you at ASCO. Dr. Charu Aggarwal: Thank you so much. This was great and I remain so excited by all of the possibilities to improve outcomes for our patients. Dr. Vamsi Velcheti: Thank you to all the listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:  Dr. Vamsidhar Velcheti  @VamsiVelcheti  @vamsivelcheti.bsky.social Dr. Charu Aggarwal @CharuAggarwalMD   Follow ASCO on social media:  @ASCO on X (formerly Twitter)  ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Vamsidhar Velcheti:  Honoraria: Glavanize Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Takeda, Janssen Oncology, Picture Health, Regeneron Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline  Dr. Charu Aggarwal: Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, Abbvie Speakers' Bureau: AstraZeneca (an immediate family member) Research Funding (Inst): Merck Sharp & Dohme, AstraZeneca/MedImmune, Daiichi Sankyo/AstraZeneca, Lilly@Loxo, Candel Therapeutics  

Consensus is slow by design.In crypto, we've accepted the tradeoff: robustness at the cost of speed. Whether it's proof-of-work or proof-of-stake, every node reprocesses every transaction, every time. It's secure and reliable... but often overkill for most of what we actually do.What if we stopped treating every transaction like a global event? What if the base layer didn't have to decide who bought a coffee first, especially when those transactions have nothing to do with each other?Pod Network offers an alternative closer to a network of local agreements, where state can move fast, stay composable, and only invoke ordering when absolutely necessary.We sat down with Shresth Agarwal at ETHDenver to talk about rethinking onchain design. If you've ever thought about the limits of blockspace, MEV, or how far we can push latency while keeping decentralization intact, this conversation is going to give you something new to think about. Join The Rollup Edge: https://members.therollup.coWebsite: https://therollup.co/Spotify: https://open.spotify.com/show/1P6ZeYd..Podcast: https://therollup.co/category/podcastFollow us on X: https://www.x.com/therollupcoFollow Rob on X: https://www.x.com/robbie_rollupFollow Andy on X: https://www.x.com/ayyyeandyJoin our TG group: https://t.me/+8ARkR_YZixE5YjBhThe Rollup Disclosures: https://therollup.co/the-rollup-discl

In this episode, Dr. Shantanu Agrawal, Chief Health Officer at Elevance Health, discusses the company's innovative approach to addressing social determinants of health. He highlights the Elevance Health Foundation's new impact investing program, its focus on behavioral health, and how insurers can drive meaningful change in communities.

In this episode, Dr. Shantanu Agrawal, Chief Health Officer at Elevance Health, discusses the company's innovative approach to addressing social determinants of health. He highlights the Elevance Health Foundation's new impact investing program, its focus on behavioral health, and how insurers can drive meaningful change in communities.

Join Emily's brand-new Embodied Manifesting Course Ziva Magic - get 15% off with promo code WHYTHIS: https://zivameditation.com/magic What if capitalism wasn't just about profit—but about purpose? In this episode of Why Isn't Everyone Doing This?, I sit down with the legendary Miki Agrawal—serial entrepreneur, disruptor, and the creator of multiple 9-figure businesses—to unpack the game-changing concept of Conscious Capitalism. Miki has built brands that challenge norms (from period underwear to bidets to sustainable diapers) and has proven that business can be wildly profitable and make a real impact. She shares how to scale with integrity, lead with soft power, and create brands that people are obsessed with.

In this episode of PodRocket, Dev Agrawal, dev advocate and developer, talks about building efficient asynchronous UIs, the challenges and solutions for handling complex state management, utilizing React and Solid frameworks, and the potential of suspense boundaries and transitions in modern web development. Links https://devagr.me https://github.com/devagrawal09 https://www.linkedin.com/in/dev-agrawal-88449b157 https://medium.com/@devagrawal09 https://www.youtube.com/channel/UCDXzM8ijdxkVA6NbQiQCKag https://x.com/devagrawal09 https://events.codemash.org/2025CodeMashConference#/agendaday=4&lang=en&sessionId=76186000004278631&viewMode=2 We want to hear from you! How did you find us? Did you see us on Twitter? In a newsletter? Or maybe we were recommended by a friend? Let us know by sending an email to our producer, Emily, at emily.kochanekketner@logrocket.com (mailto:emily.kochanekketner@logrocket.com), or tweet at us at PodRocketPod (https://twitter.com/PodRocketpod). Follow us. Get free stickers. Follow us on Apple Podcasts, fill out this form (https://podrocket.logrocket.com/get-podrocket-stickers), and we'll send you free PodRocket stickers! What does LogRocket do? LogRocket provides AI-first session replay and analytics that surfaces the UX and technical issues impacting user experiences. Start understand where your users are struggling by trying it for free at [LogRocket.com]. Try LogRocket for free today.(https://logrocket.com/signup/?pdr) Special Guest: Dev Agrawal.

This week on the Wonderspace Podcast we orbit with Mahak Agrawal. An urban planner, climate science and sustainability expert living in Delhi. Mahak is also the founder of the creative consultancy All Bits Count or ABC which was launched during COP29 in Baku. What began as a personal journey to make climate science more accessible has now evolved into a collective of changemakers using art, science, tech, and humour to demystify sustainability challenges and promote tangible solutions.

On this episode Doug speaks with Mitesh Agrawal the CEO of Positron.ai. Positron is advancing the world of AI hardware right here in the Biggest Little City, with their first product that provides 3X the performance of NVIDA at a lower cost. They discuss the changing landscape of AI, the importance of purpose built hardware and Positrons unique value. They discuss the Positron team, their investors and their success to date as well as dive in the future for them in our region.

Mauli Agrawal is the chancellor of the University of Missouri-Kansas City. He joined KCUR's Up To Date for the series "5 Questions" to discuss music, books and the state of Kansas City.

In this episode, CJ is joined by Kapil Agrawal, CFO at Outschool, former CFO of Poshmark, and former Global Head of Pricing and Finance Business Partner at Uber. Kapil shares insights on Uber's pricing strategies and the use of promotions to drive customer growth. He discusses the multiple North Star metrics used at Uber before explaining his role in changing the company's take rate. He also talks about his role at Poshmark and how he raised the company's gross margin. The conversation explores the advantages and challenges of marketplace models versus subscription models and highlights the potential of combining both. Also covered is the significance of high-quality decision-making as a leader and the role of hard work in achieving this.—SPONSORS:MUFG is the largest bank in Japan and a global banking powerhouse with a focus on empowering Growth and Middle Market stage companies in North America and Europe. MUFG provides comprehensive banking services for VC-backed, PE-backed, and public companies with revenues starting at $40M. The bank combines its global capabilities with deep operational understanding to help companies accelerate their growth trajectory. Contact group head Bob Blee at bblee@us.mufg.jp to find out more.Brex offers the world's smartest corporate card on a full-stack global platform that is everything CFOs need to manage their finances on an elite level. Plus they offer modern banking and treasury as well as intuitive expenses and accounting automation, bill pay, and travel. Brex makes it easy to control spend before it happens, automate annoying tasks, and optimize your finances. Find out how Brex can help you make every dollar count at brex.com/metrics.Vanta's trust management platform takes the manual work out of your security and compliance process and replaces it with continuous automation. Over 9000 businesses use it to automate compliance needs across over 35 frameworks like SOC 2 and ISO 27001. Centralize security workflows, complete questionnaires up to five times faster, and proactively manage vendor risk. For a limited time, get $1,000 off of Vanta at vanta.com/metrics.Tropic is an intelligent spend management solution that consolidates your spend data and processes into one unified offering, enabling insights and decisive action. It doesn't just show you where the problems are—it helps you solve them. From spotting hidden optimization opportunities, like duplicative spend, to automating those painful procurement workflows, to giving you the best market data that turns every vendor negotiation in your favor. Tropic combines smart insights with real human expertise to keep you ahead of the curve. Visit tropicapp.io/mostlymetrics to learn how.RightRev automates the revenue recognition process from end to end, gives you real-time insights, and ensures ASC 606 / IFRS 15 compliance—all while closing books faster. Whether it's multi-element arrangements, subscription renewals, or complex usage-based contracts, RightRev takes care of it all. That means fewer spreadsheets, fewer errors, and more time for your team to focus on growth. For modern revenue recognition simplified, visit rightrev.com and schedule a demo.Planful is a financial performance management platform designed to streamline financial tasks for businesses. It helps with budgeting, closing the books, and financial reporting, all on a cloud-based platform. By improving the efficiency and accuracy of these processes, Planful allows businesses to make better financial decisions. Find out more at www.planful.com/metrics.—FOLLOW US ON X:@cjgustafson222 (CJ)—TIMESTAMPS:(0:00) Preview and Intro(02:50) Sponsor – MUFG | Brex | Vanta(07:15) Discounting and Promotions at Uber(09:26) Pros and Cons of Acquiring Customers with Promotions(13:48) How Uber Determined the Promotion Term of Nine Months(14:33) Promotional Launch Strategies Across Different Uber Platforms(17:49) Sponsor – Tropic | RightRev | Planful(21:10) The Multiple North Star Metrics at Uber(24:31) Retention for Drivers Versus Passengers(25:25) Tackling the Competition for Drivers(27:20) Changing Uber's Take Rate(31:55) Raising the Gross Margins at Poshmark(37:53) Moving from Buyer and Seller Cohorts to User Cohorts(39:20) Poshmark's Take Rate(42:46) Intro to Outschool(43:20) Transaction-Based Models Versus Subscription-Based Models(45:04) The Role of Capital Allocation(47:22) Combining Transaction-Based and Subscription-Based Models(49:45) Being Judged on the Quality of Your Decisions(54:00) Hiring: Generalists Versus Specialists(56:06) Long-Ass Lightning Round: A Price Cut Regret(57:34) Advice to Younger Self(58:44) Finance Software Stack(59:28) Craziest Expense Story Get full access to Mostly metrics at www.mostlymetrics.com/subscribe

What are psychedelics? How do they impact your brain? Are they safe? Parker and Emma unpack the current research and legality of psychedelics and discuss the ethical implications of psychoactive drugs. Sources: Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025). Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism. The American Journal of Bioethics, 25(1), 16–28. Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., … Vaidya, V. A. (2024). Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. Neuron, 112(22), 3697-3714. Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. Healthcare Professionals. Scientific Reports, 14(1), 28022. Davis, A. K., Bates, M., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., … Yehuda, R. (2024). The Epidemiology of Psychedelic Use Among United States Military Veterans. Journal of Psychoactive Drugs, 1–14. Published Online. September 12, 2024. Ehrenkranz, R., Agrawal, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events should not be surprising in psychedelic research. Psychedelic Medicine. Published Online. September 4, 2024. Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics. JAMA Psychiatry, 81(12), 1225-1235. Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024). Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nature Reviews Psychology, 3(9), 606–621. Goldy, S. P., Hendricks, P. S., Keltner, D., & Yaden, D. B. (2024). Considering distinct positive emotions in psychedelic science. International Review of Psychiatry, 1–12. Published Online. September 2, 2024. Heller, N. H. & Barrett, F. S. (2024). Teaching a new dog old tricks: bringing rigor, grounding, and specificity to psychedelic neuropsychopharmacology. Neuropsychopharmacology. Published Online. August 26, 2024. Yaden, D. B., Mathai, D., Bogenschutz, M., & Nichols, D. E. (2024). The pharmacology of hallucinogens. In: Miller et al. (Eds.). Principles of Addiction Medicine. American Society of Addiction Medicine. Yaden, D. B., Nayak, S. M., Griffiths, R. R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In: C. Letheby (Ed.). Philosophy and the psychedelic renaissance. Oxford University Press, New York. DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher-Stine, L., & Griffiths, R. R. (2024). Impact of psilocybin on peripheral cytokine production. Psychedelic Medicine, 2(2). Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B. (2024). Psychedelic group-based integration: Ethical assessment and initial recommendations. International Review of Psychiatry, 1–11. Tiwari, P., Ehrenkranz, R., & Yaden, D. B. (2024). Psychiatric Applications of Psychedelics: Neurobiological Foundations for Treatments of Depression, Anxiety, and Obsessive-Compulsive Disorder. Advances in Psychiatry and Behavioral Health. McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open, 7(6), e2414650.

Sanjay Agrawal is a visionary leader and the Executive Director at Ramesh Corp., a prominent company making significant strides in multiple industries in Nepal. With a keen eye on innovation and market trends, Sanjay is dedicated to steering the company toward a future of growth and diversification.

This episode is sponsored by Netsuite by Oracle, the number one cloud financial system, streamlining accounting, financial management, inventory, HR, and more.   NetSuite is offering a one-of-a-kind flexible financing program. Head to  https://netsuite.com/EYEONAI to know more.  In this episode of the Eye on AI podcast, we dive into the transformative world of AI compute infrastructure with Mitesh Agrawal, Head of Cloud/COO at Lambda   Mitesh takes us on a journey from Lambda Labs' early days as a style transfer app to its rise as a leader in providing scalable, deep learning infrastructure. Learn how Lambda Labs is reshaping AI compute by delivering cutting-edge GPU solutions and accessible cloud platforms tailored for developers, researchers, and enterprises alike.   Throughout the episode, Mitesh unpacks Lambda Labs' unique approach to optimizing AI infrastructure—from reducing costs with transparent pricing to tackling the global GPU shortage through innovative supply chain strategies. He explains how the company supports deep learning workloads, including training and inference, and why their AI cloud is a game-changer for scaling next-gen applications.   We also explore the broader landscape of AI, touching on the future of AI compute, the role of reasoning and video models, and the potential for localized data centers to meet the growing demand for low-latency solutions. Mitesh shares his vision for a world where AI applications, powered by Lambda Labs, drive innovation across industries.   Tune in to discover how Lambda Labs is democratizing access to deep learning compute and paving the way for the future of AI infrastructure.   Don't forget to like, subscribe, and hit the notification bell to stay updated on the latest in AI, deep learning, and transformative tech! Stay Updated: Craig Smith Twitter: https://twitter.com/craigss Eye on A.I. Twitter: https://twitter.com/EyeOn_AI (00:00) Introduction and Lambda Labs' Mission (01:37) Origins: From DreamScope to AI Compute Infrastructure (04:10) Pivoting to Deep Learning Infrastructure (06:23) Building Lambda Cloud: An AI-Focused Cloud Platform (09:16) Transparent Pricing vs. Hyperscalers (12:52) Managing GPU Supply and Demand (16:34) Evolution of AI Workloads: Training vs. Inference (20:02) Why Lambda Labs Sticks with NVIDIA GPUs (24:21) The Future of AI Compute: Localized Data Centers (28:30) Global Accessibility and Regulatory Challenges (32:13) China's AI Development and GPU Restrictions (39:50) Scaling Lambda Labs: Data Centers and Growth (45:22) Advancing AI Models and Video Generation (50:24) Optimism for AI's Future (53:48) How to Access Lambda Cloud  

In this episode of Gradient Dissent, Akshay Agrawal, Co-Founder of Marimo, joins host Lukas Biewald to discuss the future of collaborative AI development. They dive into how Marimo is enabling developers and researchers to collaborate seamlessly on AI projects, the challenges of scaling AI tools, and the importance of fostering open ecosystems for innovation. Akshay shares insights into building a platform that empowers teams to iterate faster and solve complex AI challenges together.Follow Weights & Biases:https://twitter.com/weights_biases https://www.linkedin.com/company/wandb Join the Weights & Biases Discord Server:https://discord.gg/CkZKRNnaf3

In this compelling podcast interview, Priyanka Chaturvedi Agrawal, co-founder of Inclusional, explores the transformative power of tech-driven diversity and inclusion strategies in modern workplaces. Drawing from her extensive corporate experience, she advocates for a data-driven approach that goes beyond tokenism, emphasizing how diverse talent directly correlates with business growth and profitability. Priyanka highlights the critical importance of workplace safety, clean data analytics, and AI-powered insights in creating truly inclusive environments that benefit both employees and organizations.  00:37- About Priyanka Chaturvedi Agrawal Priyanka is a co-founder and head of Inclusional, which is a pioneering tech inclusion and diversity consulting firm under JetSynthesys.  She's also a certified psychotherapist, REBT practitioner, and inclusion specialist. --- Support this podcast: https://podcasters.spotify.com/pod/show/tbcy/support

In this podcast, we dive into the revolutionary world of Inhabitr with our special guest, Ankur Agrawal, the visionary founder of the first fully integrated platform-as-a-service furniture company. Discover how Inhabitr is redefining furnishing with flexible subscription, purchase, and pre-owned options across sectors like hospitality, multifamily housing, staging, student housing, short-term rentals (STR), and direct-to-consumer markets. Learn how their platform leverages AI-powered technology and a proprietary supply chain to provide a wide variety of furniture options curated by in-house designers. We also discuss their impressive achievement of raising a total of $31 million, including $27 million in Series B funding from Hamilton Ventures. Ankur Agrawal also shares his personal journey, relocating from Chicago, where he had a successful career at McKinsey & Company, to Silicon Valley to pursue his dream. Headquartered in San Francisco and Mumbai, Inhabitr is transforming the furniture rental industry with innovative and affordable solutions. Tune in to hear Ankur's insights on innovation, entrepreneurship, and the future of flexible furnishing solutions!

On this episode of Biotalk, Geoff Meyerson, CEO and Co-founder of Locust Walk, speaks with Sudhir Agrawal, Founder and President of ARNAY Sciences and a pioneer in RNA therapeutics. Sudhir's extensive career spans over three decades, during which he has made groundbreaking contributions to the field, including developing gapmer antisense technology, immune modulation approaches, and, in recent years, designing cyclic structures of DNA and RNA for therapeutic applications. In their conversation, Sudhir recounts his journey from his early days in nucleic acid research to becoming a leading innovator in RNA therapeutics. He delves into the origins of the gapmer technology, its impact on antisense drug development, and the lessons learned from his time Idera Pharmaceuticals. He also shares insights into his latest work on cyclic RNA/DNA structures and discusses his vision for the future of nucleic acid therapeutics. He concludes by offering practical advice to entrepreneurs aspiring to break into the biotech space and sharing his thoughts on the future of RNA science. Join us for a deep dive into the world of RNA therapeutics with one of its most influential figures.Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 1:34 What inspired you to focus specifically on RNA therapeutics, and how did your whole journey here begin?  3:04 Can you provide more details about the initial insight behind the development of the gapmer technology, which has been transformational for the space?  5:34 What lessons did you learn from your experience at Ionis (formerly Isis) that you would apply to your current work?  13:54 How are you thinking about commercializing the cyclic RNA/DNA structures you have developed at your company RNA Sciences?  23:40 Beyond the cyclic structures, what other innovations or areas of focus do you see on the horizon for nucleic acid therapeutics?  23:23 What advice would you give your early self starting out as an entrepreneur and innovator in the biotech space? 

How will the incoming Trump administration handle challenges in China, the Middle East, Russia and Ukraine? Join Major as he goes around the world with the editor-in-chief of Foreign Policy, Ravi Agrawal. This episode was recorded on November 22, 2024.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Medsider Radio, we sat down with Dhruv Agrawal, CEO of Aether Biomedical. Aether's ZEUS bionic arm is a highly durable, multi-articulating prosthetic designed to handle everyday tasks with improved grip strength and resilience.Dhruv found his true calling in building prosthetics while he was studying medicine and proceeded to co-found Aether when he was 18. Since starting Aether, he has helped raise over $15 million in funding and guided the launch of the ZEUS bionic hand, now deployed worldwide, including those impacted by the war in Ukraine.In this interview, Dhruv discusses the importance of defining a clear problem statement, his approach to using grants to supplement VC funding, and the lessons he's learned about evaluating market opportunities while operating globally.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ lifescience investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dhruv Agrawal.

Celebrating Powerhouse Women salutes and recognizes women who are making an impact, whether it's in business, philanthropy, public service, or elsewhere. Amita Agrawal McClain/My Easy School Supply Amita Agrawal McClain, the Founder of My Easy School Supply, was born and raised in Nepal and now lives in Duluth, GA. She wanted to make a difference […] The post Amita Agrawal McClain, Founder of My Easy School Supply appeared first on Business RadioX ®.

Celebrating Powerhouse Women salutes and recognizes women who are making an impact, whether it's in business, philanthropy, public service, or elsewhere. Amita Agrawal McClain/My Easy School Supply Amita Agrawal McClain, the Founder of My Easy School Supply, was born and raised in Nepal and now lives in Duluth, GA. She wanted to make a difference […]

In this enlightening episode of Healthy AF, Amy sits down with a special guest, her friend and expert pelvic floor physical therapist, Dr. Aakriti. Dive deep into their personal and professional growth journeys, tackling the struggles that come with it. They'll share insights on overcoming comparison, enhancing self-worth, managing work schedules, and ultimately, taking responsibility for creating healthy, balanced lives they adore. Whether you're looking for tips on physical health or seeking inspiration for personal development, this conversation promises valuable takeaways for crafting a life filled with love and balance. Tune in to a vulnerable conversation between friends who empower and support a life well lived!Connect with Amy hereConnect with Aakriti hereTrying to get healthy and stay healthy is f-ing hard! Everybody struggles with some aspect of it, no matter what they look like or what they tell you. There is no magic formula - a healthy lifestyle is a choice we need to make daily. Join Amy as she supports, informs, and entertains you on your journey toward health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode explores the nakshatras, the fundamental concept of the Vedic astrological system. Nakshatras refer to the division of the sky into 27 equal segments, each named after a prominent star. Aligning with the 12 zodiac signs, nakshatras are considered a cosmic clock, with one day passing as the moon moves through each nakshatra, repeating every 27 days.  Bibliography: Padmanabham, T. (2017). History of Indian Astronomy. Springer. Dixit, B., & Sewell, R. (2013). Indian Calendar. Subbarayappa, B. V. (2004). The history of Indian astronomy. Springer. Harness, D. M. (1999). The nakshatras: The lunar mansions of Vedic astrology. Lotus Press. Agrawal, D. P. (2004). India's scientific heritage. Pearson Education India. Kelley, D. H., & Milone, E. F. (2005). Exploring ancient skies: An encyclopedic survey of archaeoastronomy. Springer Science & Business Media. Rao, S. B. (2000). Astronomy in India: A historical perspective. Universities Press. Topic: History of India | Astronomy | Astrology | Indian mythology | Hindu mythology | Hinduism Ko-fi: ⁠⁠http://ko-fi.com/namaskarindia⁠⁠ UPI ID: 9893547492@paytm Paypal: ⁠⁠⁠https://www.paypal.com/paypalme/aduppala⁠⁠⁠ Instagram: ⁠⁠⁠https://www.instagram.com/namaskarindialive/⁠⁠⁠⁠ Facebook: ⁠⁠⁠https://www.facebook.com/namaskarindialive⁠⁠⁠ Twitter: ⁠⁠⁠https://twitter.com/AradhanaDuppala⁠⁠⁠ Youtube: ⁠⁠⁠https://www.youtube.com/c/NamaskarIndia⁠⁠⁠ WhatsApp Discussions: ⁠⁠https://chat.whatsapp.com/H8IUJPlB32cA2soTjrTghV⁠⁠ WhatsApp Announcements: ⁠⁠https://chat.whatsapp.com/KVd5UHxumW90TxLHjkB89k⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/namaskar-india/support

Jupyter has been a great environment to explore computational ideas, but that doesn't mean that it can be the only environment for interactive coding in Python. It also comes with some downsides, which led Akshay Agrawal to create an alternative called Marimo. We discussed it in a previous livestream and figured that it was time to sit down with the creator to learn what led to the development of this exciting new too. You can learn more about Marimo by going to their website over at https://marimo.io To learn more you can check out website or reach out to us on social media. Website: https://probabl.ai/ LinkedIn: https://www.linkedin.com/company/probabl Twitter: https://x.com/probabl_ai

In this episode, Daniel Arnold sits down with Dr. Gautam Agrawal Dr. Gautam Agrawal is a subspeciality-trained Musculoskeletal Radiologist with a master's in Nuclear Engineering and a driven entrepreneurial spirit. Dr. Agrawal and Co-Founder Dr. Ray Hsu established Vision Radiology, an academically oriented teleradiology practice, in 2003 while co-residents at Johns Hopkins Hospital. His technical background has served as a foundation for working at the intersection of health and technology. Dr. Agrawal discusses the unique team-based workflow that fosters collaboration among radiologists, the challenges of scaling while preserving core values, and his passion for education and innovation in radiology.  Learn more at https://medality.com/the-radiology-report-podcast Like this episode? We'd love it if you could leave us a five-star review! And make sure to subscribe, so you never miss an opportunity to hear from the leaders in radiology.

Welcome to another episode of Category Visionaries — the show that explores GTM stories from tech's most innovative B2B founders. In today's episode, we're speaking with Pulkit Agrawal, CEO & Co-Founder of Chameleon, a product adoption platform that has raised $15 Million in funding. Here are the most interesting points from our conversation: The Power of Onboarding: Pulkit shared how Chameleon was born from a personal experience with user onboarding, and how a simple project to revamp onboarding boosted user retention significantly. Evolution of Positioning: Initially focused on user onboarding, Chameleon later embraced the broader category of product adoption platforms, inspired in part by market trends and competitive positioning. Category Challenges: Pulkit discussed the struggle of accepting and operating within an existing category, like "Digital Adoption Platforms," and how Chameleon aims to differentiate itself while playing in that space. PLG Misconceptions: Many companies fail with product-led growth (PLG) because they think of it as an all-or-nothing shift. Pulkit emphasizes the importance of small, iterative changes and learning from current users for PLG success. Sophisticated Sales Process: Pulkit highlighted the shift from convincing companies to adopt new tools to winning customers over from competitors, which requires a more sophisticated sales process and depth of product knowledge. Content-Led Growth: Pulkit underscored the value of high-quality content in driving inbound growth and how he has taken a hands-on approach to produce valuable, expert-level material, like a comprehensive guide on Digital Adoption Platforms. //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.  www.GlobalTalent.co

Social media during election season? Yeah, it's a lot, right?

It's hard to escape talk of AI these days, but not all AI is the same, and not all of it is safe for large organizations to use. Today we're diving into the evolving world of generative AI for the enterprise with Sumeet Agrawal, VP of Product Management at Informatica. We'll discuss strategies and considerations for building robust, enterprise-grade generative AI applications. Sumeet Kumar Agrawal is a VP of Product Management at Informatica. Based in the Bay Area, Sumeet has 15+ years of data engineering and product management experience, driving innovative products within the cloud technology sector. He leads the Cloud AI/GenAI, Analytics & Data warehouse & Data lake, and iPaaS product portfolio at Informatica. It consists of multiple product lines such as Cloud Data Engineering, Streaming, big data, NoSQL, Serverless, Cloud Mass Ingestion(including CDC), Serverless & AI/ML, GenAI, API, and App Integration initiatives. He has a lot of experience working with many cloud ecosystem vendors like AWS, GCP, Azure, Snowflake, Databricks, etc. Apart from this, Sumeet has been frequently recognized as a strong communicator who has successfully worked with people from broad socio-economic backgrounds, and diverse cultures, building strong and fruitful organizational teams. He sits on the advisory board of many startups. RESOURCES Informatica website: https://www.informatica.com Register for the Medallia CX Day webinar: Building Loyalty: How Top Brands Create Forever Customers with CX - https://bit.ly/3M7dkQM Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstrom Don't miss a thing: get the latest episodes, sign up for our newsletter and more: https://www.theagilebrand.show Attend the Mid-Atlantic MarCom Summit, the region's largest marketing communications conference. Register with the code "Agile" and get 15% off. Register now for HumanX 2025. This AI-focused event which brings some of the most forward-thinking minds in technology together. Register now with the code "HX25p_tab" for $250 off the regular price. Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://www.teksystems.com/versionnextnow The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Epigenetics Podcast, we caught up with Vladimir Teif from the University of Essex to talk about his work on nucleosome positioning in development and disease. Vladimir's research has been pivotal in understanding nucleosome positioning and its implications for cell differentiation, particularly in embryonic stem cells and cancer. We discuss his groundbreaking studies that first mapped nucleosome positions in various cell types and how these findings led to uncovering the intricate relationships between nucleosome stability, transcription factors, and DNA modifications such as methylation. This understanding has immense significance for cancer diagnostics, where knowing the spatial arrangement of nucleosomes could influence how aggressive a cancer type might be, or how a patient might respond to treatment. Transitioning from foundational research to clinical applications, Vladimir elaborates on his exciting work with liquid biopsies. By analyzing cell-free DNA from blood plasma, researchers can infer the nucleosome positioning and, ultimately, the presence of cancer without the need for invasive tissue biopsies. We explore how this new approach holds potential for earlier detection of cancers and more effective patient stratification, demonstrating a profound shift in how we leverage epigenetic data in clinical settings.   References Vladimir B. Teif, Karsten Rippe, Predicting nucleosome positions on the DNA: combining intrinsic sequence preferences and remodeler activities, Nucleic Acids Research, Volume 37, Issue 17, 1 September 2009, Pages 5641–5655, https://doi.org/10.1093/nar/gkp610 Teif, V., Vainshtein, Y., Caudron-Herger, M. et al. Genome-wide nucleosome positioning during embryonic stem cell development. Nat Struct Mol Biol 19, 1185–1192 (2012). https://doi.org/10.1038/nsmb.2419 Beshnova DA, Cherstvy AG, Vainshtein Y, Teif VB (2014) Regulation of the Nucleosome Repeat Length In Vivo by the DNA Sequence, Protein Concentrations and Long-Range Interactions. PLoS Comput Biol 10(7): e1003698. https://doi.org/10.1371/journal.pcbi.1003698 Shtumpf, M., Piroeva, K.V., Agrawal, S.P. et al. NucPosDB: a database of nucleosome positioning in vivo and nucleosomics of cell-free DNA. Chromosoma 131, 19–28 (2022). https://doi.org/10.1007/s00412-021-00766-9   Related Episodes Circulating Epigenetic Biomarkers in Cancer (Charlotte Proudhon) Epigenome-based Precision Medicine (Eleni Tomazou)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

Today my guest is Amol Agrawal, who is the author of History of Private Banking in South Canara District (1906-69). He teaches economics at Ahmedabad University and blogs at the excellent blog Mostly Economics.  We spoke about the colonial and post-colonial history of banking in India, the unique features of the South Canara district, and its bankers, inclusive banking by state and private banks, bank nationalization, and much more.  Recorded July 26th, 2024. Read a full transcript enhanced with helpful links. Connect with Ideas of India Follow us on X Follow Shruti on X Follow Amol on X Click here for the latest Ideas of India episodes sent straight to your inbox. Timestamps (00:00:00) - Intro (00:01:21) - History of Private Banking in India (00:12:06) - Lending and Deposits (00:16:17) - Industrial Development and Banking (00:21:24) - Bank Runs in India (00:25:54) - Success of South Canara Banks (00:28:38) - Systemic Risk in South Canara (00:36:16) - Banking Castes? (00:40:29) - What was the RBI so wrong about with South Canara banking? (00:47:50) - Pigmy Deposit Scheme (01:05:28) - Why Were India's Banks Nationalized? (01:23:35) - Outro 

The first episode of the HRT after breast cancer series features oncologist Dr. Leila Agrawal, who discusses the evidence, studies, and trials regarding HRT for breast cancer patients.Dr. Laila Agrawal is a medical oncologist and haematologist specialising in treating breast cancer patients. She is involved in research and clinical trials and she strives to get to know every patient and learn what is important in their lives, from their families to their goals, and how that plays into important decisions about their health.This mini-series explores hormone replacement therapy (HRT) after breast cancer, a controversial and emotive subject. The conversation focuses on the further understanding of risks and benefits of HRT (hormone replacement therapy) or also MHT (menopause hormone therapy), the emotional impact on patients, and the different views among medical professionals. The goal is to provide understanding for patients seeking HRT after breast cancer and insight for doctors on how to move forward without robust evidence. Dani Binnington, host of the Menopause And Cancer podcast, and founder of the not-for-profit organisation Menopause And Cancer has spoken to hundreds of women who feel like they are in a void and have nowhere to turn to in discussing this difficult topic. Welcome to our HRT after breast cancer series.In this episode we discuss:The role of hormone-blocking medications such as tamoxifen and aromatase inhibitors for breast cancer survivors.Dr. Agrawal discusses many studies on HRT after breast cancer, including the The Habits study which showed an increased risk of recurrence in the HRT group, leading to the trial being stopped early.She goes on to explain The Stockholm study which did not show an increased risk of recurrence.Dr. Agrawal explains other studies, including observational studies that looked at the use of hormone replacement therapy after breast cancer and explains the outcome of meta-analysis for different types of breast cancers. We discuss what these study results mean for different types of cancers, such as triple-negative breast cancer. Dr. Agrawal discusses the difference between absolute risk and relative risk is and why this is important when interpreting data.Additional research is needed to determine the safety and efficacy of HRT in breast cancer survivors.Episode Highlights: 00:00 Intro.04:19 Understanding patient perspectives and ethical medical decisions.08:10 Different types of breast cancer treatment options.09:52 Aromatase inhibitors used to treat breast cancer.17:01 Breast cancer trial halted due to risk.25:05 Stockholm Study.37:14 Interpreting risk reduction impact of treatments accurately.48:04 Data on tamoxifen and HRT remains inconclusive.53:25 Understanding and quantifying medical risks for patients.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

Welcome to Growthmates with Kate Syuma — Growth advisor, previously Head of Growth Design at Miro. I'm building Growthmates as a place to connect with inspiring leaders to help you grow yourself and your product. Here you can learn how companies like Dropbox, Adobe, Canva, Loom, and many more are building excellent products and growth culture. Get all episodes and a free playbook for Growth teams on our brand-new website — growthamtes.club, and press follow to support us on your favorite platforms. Listen now and subscribe on your favorite platforms — Apple, Spotify, or watch on YouTube (new!).—In this episode, I chat with Amy Bucher, Chief Behavioral Officer at Lirio and author of Engaged. We delve into the world of behavioral design, exploring how understanding human behavior can lead to more ethical and effective product development. Amy shares her journey from academia to leading behavioral design teams, and how frameworks like the COMBEE model and Behavior Change Wheel are essential tools for influencing user behavior.By the end of this episode, you'll learn how to apply behavioral science principles to your product, understand the importance of ethical design, and gain insights into leveraging AI for personalized user experiences

Paulina Rowinska is a writer, mathematician and science communicator, whose new book, Mapmatics: How We Navigate the World Through Numbers, tells the stories found within crunching tricky equations. Rowinska has a PhD in Mathematics of Planet Earth from Imperial College London and across the pages of Mapmatics she explores fields ranging from map-making to forecasting elections, how we get our packages delivered on time and even how mathematics can be used to prevent crime. Joining her to discuss it is Roma Agrawal, MBE, who is a structural engineer, author and broadcaster. Agrawal has written three books, the most recent of which is Nuts & Bolts, which was shortlisted for the 2023 Royal Society Science Book Prize. Her new children's book, Seven Small Inventions that Changed the World, is out in late August. Find out more at www.Romatheengineer.com. We are sponsored by Indeed. Go to Indeed.com/IS for £100 sponsored credit. If you'd like to become a Member and get access to all of our longer form interviews and Members-only content, just visit intelligencesquared.com/membership to find out more. For £4.99 per month you'll also receive: - Full-length and ad-free Intelligence Squared episodes, wherever you get your podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series - 15% discount on livestreams and in-person tickets for all Intelligence Squared events - Our member-only newsletter The Monthly Read, sent straight to your inbox ... Or Subscribe on Apple for £4.99: - Full-length and ad-free Intelligence Squared podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series ... Already a subscriber? Thank you for supporting our mission to foster honest debate and compelling conversations! Visit intelligencesquared.com to explore all your benefits including ad-free podcasts, exclusive bonus content and early access. ... Subscribe to our newsletter here to hear about our latest events, discounts and much more. https://www.intelligencesquared.com/newsletter-signup/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of DGTL Voices, Ed talks with Sachin Agrawal, CEO of e-Visit. They discuss Sachin's background, the mission and vision of e-Visit, and the importance of personal growth in leadership. He also emphasizes the value of surrounding oneself with a personal board of directors and finding inspiration in difficult times. The conversation concludes with a discussion on the transformation of healthcare and the role of leaders in driving change.   Key Takeaways The CEO role is a vehicle for personal growth, and aspiring leaders should embrace personal growth as they pursue their careers. Building teams with a growth mindset and a positive sum game mindset can lead to greater success and collaboration. Surrounding oneself with a personal board of directors can provide support, accountability, and inspiration in challenging times. e-Visit's mission is to simplify healthcare delivery for everyone everywhere, and they have had success in public health applications.

Level Supermind - Mind Performance App को Download करिए यहाँ से

What does the surprising outcome of the Indian elections mean for the state of democracy there? Zachary and Emma delve into the failure of polling predictions and discuss the implications of the election results with Ravi Agrawal, the editor-in-chief of Foreign Policy. The conversation looks towards India's future growth and the challenges it faces. While India has the potential to attract companies and become a destination for business, average incomes remain low, and further reforms are needed. What Could Go Right? is produced by The Progress Network and The Podglomerate. For transcripts, to join the newsletter, and for more information, visit: theprogressnetwork.org Watch the podcast on YouTube: https://www.youtube.com/theprogressnetwork And follow us on X, Instagram, Facebook, TikTok: @progressntwrk Learn more about your ad choices. Visit megaphone.fm/adchoices

Part 1 of 2: Join Amy and Dr. Aakriti Agrawal, the force behind No Pelvis Left Behind, as we dive deep into the often misunderstood world of urinary incontinence, low back pain, SI joint discomfort, and more. In this revealing two-part episode, we shatter common myths about the "normals" of aging, painful sex, and debilitating menstrual symptoms. Hear Amy's personal journey and discover if it resonates with you. Dr. Aakriti's experience shows that these issues are not exclusive to women—men's struggles with testicular and penile pain, and dribbling and urgency (particularly after prostate procedures and infection) are real and addressable. Whether you're male or female, young or old, join us to learn that you're not alone and that hope and healing are within reach. Let's get Healthy AF together! Trying to get healthy and stay healthy is f-ing hard! Everybody struggles with some aspect of it, no matter what they look like or what they tell you. There is no magic formula - a healthy lifestyle is a choice we need to make daily. Join Amy as she supports, informs, and entertains you on your journey toward health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Part 1 of 2: Join Amy and Dr. Aakriti Agrawal, the force behind No Pelvis Left Behind, as we dive deep into the often misunderstood world of urinary incontinence, low back pain, SI joint discomfort, and more. In this revealing two-part episode, we shatter common myths about the "normals" of aging, painful sex, and debilitating menstrual symptoms. Hear Amy's personal journey and discover if it resonates with you. Dr. Aakriti's experience shows that these issues are not exclusive to women—men's struggles with testicular and penile pain, and dribbling and urgency (particularly after prostate procedures and infection) are real and addressable. Whether you're male or female, young or old, join us to learn that you're not alone and that hope and healing are within reach. Let's get Healthy AF together! Trying to get healthy and stay healthy is f-ing hard! Everybody struggles with some aspect of it, no matter what they look like or what they tell you. There is no magic formula - a healthy lifestyle is a choice we need to make daily. Join Amy as she supports, informs, and entertains you on your journey toward health. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this conversation, I speak with Abhishek Agrawal, co-founder and CEO of Material Security. We talk about: - Material's Security innovative approach to email security by not just preventing unauthorized access but also containing damage from potential breaches. -Abhishek's background in data infrastructure at Dropbox and how product mangers can become successful CEOs due to their cross-functional expertise.  - The need for customized security measures for different organizations, the role of AI in detecting email threats, the importance of single-tenant environments for sensitive customers and the potential risk of default settings in productivity suites like Google Workspace. Among other topics.  Abhishek's Background and Material Security (00:00:00)Email Security and Productivity Suite (00:01:01)Geographical Connection and Coffee Meetup (00:02:06)Product Managers as CEOs and Co-founders (00:02:59)Empowering Product Managers (00:05:01)Product Management and Marketing Importance (00:08:04)Email as a Content Repository (00:09:39)Securing Email Content (00:11:03)Data Protection for Email (00:12:10)Redacting and Canaries (00:12:57)Email Security vs. Data Security (00:14:53)Abuse Cases and Control Layers (00:17:32)Mailbox Compromise and Lateral Movement (00:17:39)Threat Scenario Analysis (00:20:15)Language Models for Detection (00:22:19)Optimism in AI Tools for Defense (00:24:34)Customized Detection Categories (00:25:52)Security Controls Trend (00:26:20)Security Concerns for Law Firms (00:27:07)Email Copy Distribution (00:27:24)API-Based Integration (00:29:08)Monitoring LM Functionality (00:30:42)Threat Intelligence and Detection (00:32:54)Product Design Philosophy (00:35:56)Data Protection (00:38:01)Flexibility in Deployment (00:39:26)Main Products (00:40:33)Posture Management (00:44:01)Broadening Product Coverage (00:48:49)Google Workspace Threat Detection (00:50:05)Challenges with CSP (00:51:13)Contextual Intelligence (00:52:02)Balancing Depth and Breadth (00:53:15)Learning about Material (00:53:40)Become a Member: https://danielmiessler.com/upgradeSee omnystudio.com/listener for privacy information.

Meet Dev Agrawal

In this episode of Soul of Travel, Season 5: Women's Wisdom + Mindful Travel, presented by @journeywoman_original, Christine hosts a soulful conversation with Geetika Agrawal.Geetika is a designer, avid traveler and founder of VAWAA: Vacation With An Artist. She discovered her love for learning and travel during her early college days when she spent her summers working with local artisans in small towns of Rajasthan and Tamil Nadu in India. As she traveled to countries around the world, she sought similar experiences where she could immerse herself into the local culture, make things with her hands, and get inspired by learning something new. She noted that there were others like her expecting the same from their travels, but there was no easy way to find local artists and designers in cities they would visit, sitting at home. Thus the idea of ‘Vacation With An Artist' was born. Geetika's creative endeavors have garnered international recognition and have been prominently featured in the New York Times, SXSW, Artsy, National Geographic, Vogue, CondeNast Traveler, and more.Christine and Geetika discuss:· The importance of art in our lives and cultures· The extinction of traditional crafts and keepers of wisdom· How travel may play a role in the preservation of wisdom· How we need to be careful in our approach in bringing artists and cultural preservation into our travel experiencesJoin Christine now for this soulful conversation with Geetika Agrawal.

Dr. Anjali Agrawal is a family chiropractor, functional nutritionist, founder, and speaker. Dr. Anjali helps families navigate their journey from conception to adulthood. As the founder of Back In Balance, Dr. Anjali integrates gentle chiropractic adjustments, functional nutrition, ergonomics, and a variety of unique diagnostic testing to identify the root cause of symptoms. Key Topics: - How basic ergonomic tips for the kitchen and home can reduce your stress load - “Tech neck” and how it impacts whole body stress - The way changing your posture changes your physical response to stress - Why chewing 32 times impacts digestion - The connection between middle of the night wake-ups and afternoon digestion - How hair and saliva testing can individualize support for your entire body Get your free gift from Dr. Anjali, an anti-inflammatory guide, when you go to backinbalancehealth.com/podcast. Grab Erin's recipe book here: Dr. Anjali Agrawal is a family chiropractor, functional nutritionist, founder, and speaker. Dr. Anjali helps families navigate their journey from conception to adulthood. As the founder of Back In Balance, Dr. Anjali integrates gentle chiropractic adjustments, functional nutrition, ergonomics, and a variety of unique diagnostic testing to identify the root cause of symptoms. Key Topics: - How basic ergonomic tips for the kitchen and home can reduce your stress load - “Tech neck” and how it impacts whole body stress - The way changing your posture changes your physical response to stress - Why chewing 32 times impacts digestion - The connection between middle of the night wake-ups and afternoon digestion - How hair and saliva testing can individualize support for your entire body Get your free gift from Dr. Anjali, an anti-inflammatory guide, when you go to backinbalancehealth.com/podcast. Grab Erin's recipe book here: https://erinbkerry.com/shop-page/

Dr. Anjali Agrawal is a family chiropractor, functional nutritionist, founder, and speaker. Dr. Anjali helps families navigate their journey from conception to adulthood. As the founder of Back In Balance, Dr. Anjali integrates gentle chiropractic adjustments, functional nutrition, ergonomics, and a variety of unique diagnostic testing to identify the root cause of symptoms. Key Topics: - How basic ergonomic tips for the kitchen and home can reduce your stress load - “Tech neck” and how it impacts whole body stress - The way changing your posture changes your physical response to stress - Why chewing 32 times impacts digestion - The connection between middle of the night wake-ups and afternoon digestion - How hair and saliva testing can individualize support for your entire body Get your free gift from Dr. Anjali, an anti-inflammatory guide, when you go to backinbalancehealth.com/podcast. Grab Erin's recipe book here: Dr. Anjali Agrawal is a family chiropractor, functional nutritionist, founder, and speaker. Dr. Anjali helps families navigate their journey from conception to adulthood. As the founder of Back In Balance, Dr. Anjali integrates gentle chiropractic adjustments, functional nutrition, ergonomics, and a variety of unique diagnostic testing to identify the root cause of symptoms. Key Topics: - How basic ergonomic tips for the kitchen and home can reduce your stress load - “Tech neck” and how it impacts whole body stress - The way changing your posture changes your physical response to stress - Why chewing 32 times impacts digestion - The connection between middle of the night wake-ups and afternoon digestion - How hair and saliva testing can individualize support for your entire body Get your free gift from Dr. Anjali, an anti-inflammatory guide, when you go to backinbalancehealth.com/podcast. Grab Erin's recipe book here: https://erinbkerry.com/shop-page/

On this episode of DGTL Voices, Ed welcomes Dr. Shantanu Agrawal, the Chief Health Officer at Elevance Health. They discuss various topics related to digital transformation in the healthcare industry, including leveraging technology to improve the member experience, addressing disparities and social equity, and balancing the needs of providers and members. Dr. Agrawal shares his personal and professional journey, highlighting the importance of whole health and health equity. He also emphasizes the value of being kind and respectful in the healthcare industry. Overall, the conversation provides insights into the role of a Chief Health Officer and the mission of Elevance Health.   Takeaways Leveraging technology is crucial for scaling healthcare services and providing a personalized experience for members. Addressing disparities and social equity is a key focus for improving outcomes and ensuring health equity for all members. Balancing the needs of providers and members requires alignment around the patient and providing resources and support for providers. Continuing to evolve as a leader involves learning from peers, seeking inspiration from patients, and being open to new experiences and perspectives.

Newt talks with Professor Ajay Agrawal, a key player in the world of Artificial Intelligence and author of Power and Prediction: The Disruptive Economics of Artificial Intelligence. Agrawal discusses the rapid evolution of AI, highlighting the significant advancements made in the last decade. He explains that AI's core function is to improve prediction, but it also requires human clarity for value judgments within those predictions. Agrawal also discusses the potential for AI to dramatically increase productivity and trigger a large reallocation of capital. He predicts that AI will force society to be more explicit about value judgments and trade-offs, leading to increased transparency.See omnystudio.com/listener for privacy information.

Enjoy this video podcast on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Following your intuition can be challenging. It's especially tough after doing all the things you think will bring success, but still waking up feeling unfulfilled every morning. Meha Agrawal, CEO and Founder of Silk + Sonder, found herself in that exact situation. As the first-born child of immigrant parents, Meha's path to success was paved at a young age. After being modeled a limited vision of what success could be, Meha became a computer software engineer. Realizing that perhaps that path wasn't right for her, she turned to entrepreneurship. A lack of community led Meha to establish Silk + Sonder, her beloved journaling subscription service. Though Meha had her fears about becoming an entrepreneur, she recalls her customers and her bigger why, knowing her product helps millions at a time. Thanks for listening!  Don't forget to order Rebecca's new book, Fearless: The New Rules for Unlocking Creativity, Courage, and Success. Follow Superwomen on Instagram. Guest Website: silkandsonder.com mehaagrawal.com Social Media: IG: @silkandsonder      @mehaagrawal FB: @silkandsonder Big Ideas: The emotional risks of entrepreneurship Building safety nets and overcoming the fear of starting your own business Organically growing the community to 1,000 subscribers Learning to trust yourself in moments of fear Navigating financial risks as a founder Getting over the shame of asking for money when fundraising Overcoming a scarcity mindset and taking calculated risks Focusing on building small and steady The importance of having a sound business model Reorienting your business to meet the needs of newer generations --- Support this podcast: https://podcasters.spotify.com/pod/show/superwomen/support

In this Partnering Leadership conversation, Mahan Tavakoli speaks with Professor Ajay Agrawal, the Geoffrey Taber Chair in Entrepreneurship and Innovation and Professor of Strategic Management at the University of Toronto's Rotman School of Management. Ajay Agrawal is also the founder of the Creative Destruction Lab (CDL), a not-for-profit program for early-stage, science-based companies, and coauthor of two outstanding books on Artificial Intelligence: Prediction Machines: The Simple Economics of Artificial Intelligence and Power and Prediction: The Disruptive Economics of Artificial Intelligence. In the conversation, Professor Agrawal shared the origin of his passion for studying the intersection of technology and economics and the increasing importance of artificial intelligence for organizations as a decision-making tool that brings down the cost of prediction. Ajay Agrawal then explained why this shift would significantly impact individuals, organizations, and industries as machines enable better predictions while humans focus on the judgment required for decision-making. Finally, Ajay Agrawal shared examples of the transformative impact of the reduction in the cost of prediction and how leaders can help guide their organizations through the significant changes ahead.Some highlights:- Three people that helped shape Ajay Agrawal's career path- Why looking at AI from an economic perspective clarifies its potential to transform organizations and industries- Ajay Agrawal on the role of predictions in artificial intelligence - The importance of human judgment in decision making- How AI decision-making will redefine roles in the workplace- The disruptive economics of artificial intelligence - How generative AI such as ChatGPT works and what causes mistakes and misstatements- Ajay Agrawal on the importance of upskilling professionals - How organizations can redesign their structures and processes to take into account the new predictive world- The impact of AI on systems-level change- How organizations can leverage AI for business success- Why we're on the brink of a set of transformations that none of us have seen in our lifetimes- How AI can help create a better futureConnect with Professor Ajay Agrawal:Ajay Agrawal website Ajay Agrawal at Rotman School of Management Ajay Agrawal on LinkedIn Prediction Machines: The Simple Economics of Artificial Intelligence on Amazon Power and Prediction: The Disruptive Economics of Artificial Intelligence on Amazon Connect with Mahan Tavakoli: Mahan Tavakoli Website Mahan Tavakoli on LinkedIn Partnering Leadership Website